Business Context and Reporting Period
This Form 8-K Current Report was filed by Henry Schein, Inc. on January 20, 2010, with the report date reflecting the earliest event reported. The filing addresses corporate governance changes rather than operational or financial performance for a specific fiscal period.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is strictly informational regarding board composition and does not contain financial statements or operational metrics.
Material Changes
The material change reported is the election of a new director to the Board of Directors:
- Effective Date: January 20, 2010.
- Action: The Board elected Dr. Bradley T. Sheares to serve as a director.
- Committee Assignment: The Board intends to name Dr. Sheares to the Strategic Advisory Committee.
- Background: Dr. Sheares previously served as CEO of Reliant Pharmaceuticals, Inc. (acquired by GlaxoSmithKline in 2007) and President of U.S. Human Health at Merck & Co. He also serves on the boards of Honeywell International, The Progressive Corporation, IMS Health, and Covance Inc.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on financial performance, or discussion of risks and contingencies. The document explicitly states there are no related party transactions involving Dr. Sheares reportable under Item 404(a) of Regulation S-K and no arrangements regarding his election.
Investor Verification Checklist
- Verify the official press release dated January 25, 2010 (Exhibit 99.1) for additional details on Dr. Sheares' appointment.
- Confirm Dr. Sheares' current board affiliations and potential conflicts of interest via public records.
- Note that this filing does not impact the company's financial statements or operational guidance.